Meeting
2013 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.
Authors
Karim Fizazi
Institut Gustave Roussy, Villejuif, France
Karim Fizazi , Axel Heidenreich , Gedske Daugaard , Joaquim Bellmunt , Nathalie Germann , Eric Chetaille
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01732549
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS5098^)
DOI
10.1200/jco.2013.31.15_suppl.tps5098
Abstract #
TPS5098^
Poster Bd #
43A
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Giulia Baciarello
Poster
2016 Genitourinary Cancers Symposium
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.
First Author: Karim Fizazi
Poster
2013 Genitourinary Cancers Symposium
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
First Author: Susan Halabi
Poster
2021 Genitourinary Cancers Symposium
Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Mallika Marar